About

LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb's Syracuse manufacturing site. Furthermore, with a plan for Mega Plants in Korea with a total capacity exceeding 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse site is 35,000L (5,000L x7), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse site has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market. The Mega Plants in South Korea, with a total capacity exceeding 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Mega Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en About LOTTE BIOLOGICS LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb's Syracuse manufacturing site. Furthermore, with a plan for Songdo Bio Campus in Korea with a total capacity up to 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse Bio Campus is 40,000L (5,000L x8), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse Bio Campus has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market, which is projected to be fully in operation by Q1 2025. The Songdo Bio Campus in South Korea, with a total capacity up to 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Songdo Bio Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en About LOTTE BIOLOGICS LOTTE BIOLOGICS is a global CDMO company committed to provide good quality biopharmaceutical products that enable a healthier world. Since established in 2022, with unwavering dedication and distinction, LOTTE BIOLOGICS has successfully transformed into a global CDMO company following the acquisition of Bristol Myers Squibb's Syracuse manufacturing site. Furthermore, with a plan for Songdo Bio Campus in Korea with a total capacity up to 360,000L, LOTTE BIOLOGICS aims to become a Global Top 10 CDMO company in the biopharmaceutical industry. In terms of capabilities, LOTTE BIOLOGICS can offer a comprehensive range of services, from cell line development to clinical and commercial supply of Biologics Drug Substance manufacturing. The production capacity at the Syracuse Bio Campus is 40,000L (5,000L x8), along with multiple 1,100 L bioreactors for clinical product production, QC testing laboratories, a warehouse, cell bank and product storage and other related facilities. In addition, the Syracuse Bio Campus has a proven regulatory track record with more than 62 global approvals including from FDA, EMA, PMDA and MFDS. In addition, ADC conjugation facility is currently being installed to meet the increasing demand in the market, which is projected to be fully in operation by Q1 2025. The Songdo Bio Campus in South Korea, with a total capacity up to 360,000L, are scheduled to be GMP ready starting from the year of 2026. In order to foster growth and innovation in the biopharmaceutical industry, “LOTTE Bio Initiatives” will be established on the Songdo Bio Plant Campus to provide a platform for bioecosystem. Together with our partners, LOTTE BIOLOGICS is dedicated to providing reliable solution for development, manufacturing and supply of the biopharmaceutical products. For more information, please visit https://www.lottebiologics.com/en LOTTE BIOLOGICS was established in 2022 and is headquartered in Seoul, South Korea. Utilizing a two-track strategy of acquiring and building, LOTTE BIOLOGICS is solidifying its competitiveness in the CDMO market. At the Syracuse Bio Campus in New York, LOTTE BIOLOGICS provides high-quality GMP manufacturing services for drug substances. The facility offers a total production capacity of 40,000L, supported by eight 5,000L stainless steel bioreactors. Additionally, the campus includes extensive analytical QC testing laboratories and warehouse facilities that have received over 62 regulatory approvals from agencies worldwide. LOTTE BIOLOGICS is also advancing into a new area of expertise with Antibody-Drug Conjugates (ADCs) services. With over $100 million invested in ADC modalities, including both drug substance and conjugation capabilities on-site, we offer a seamless, end-to-end service from drug substance manufacturing to conjugation. Looking ahead, LOTTE BIOLOGICS is constructing three advanced bio plants in Songdo, South Korea. With construction of the first plant already underway and expected to be operational by 2027, each facility will feature eight 15,000L stainless steel bioreactors for large-scale commercial production, along with multiple 3,000L bioreactors to meet clinical production needs. Collectively, these plants will provide a manufacturing volume exceeding 360,000L in bioreactor capacity. Through our commitment to delivering innovative medicines to patients worldwide, LOTTE BIOLOGICS aims to become a top-tier global CDMO company in the biopharmaceutical industry.